IDEXX (IDXX) Q2 2026 Earnings Call Transcript
IDEXX (IDXX) reported Q2 2026 results and an earnings call transcript. Premium instrument placements topped 5,200 units, including about 1,600 inVue Dx analyzers. Q2 EPS was $4.27. IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94, citing recurring revenue growth and margin expansion.
How this was made
The 30-second read
Why it matters
Traders can update 2026 revenue and EPS models immediately using the raised ranges, while monitoring recurring revenue growth drivers (CAG Diagnostics, VetLab consumables, reference lab) versus wellness-visit softness and FX effects.
Market read
Raised 2026 revenue and EPS guidance, supported by recurring revenue growth and margin expansion, is the primary tradable catalyst.
What to watch
FX headwinds and the instrument revenue decline from lapping inVue Dx availability could create volatility in quarterly revenue mix even if full-year guidance holds.
Background
The article is an IDEXX Q2 2026 earnings call transcript covering segment performance, margins, cash flow, and an updated full-year outlook.
Ticker impact
IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94 after Q2 EPS of $4.27.
Likely positive near-term bias as traders reprice 2026 estimates toward the raised revenue and EPS ranges.
The transcript includes explicit updated full-year revenue and EPS ranges, supported by reported Q2 EPS growth and margin expansion, which are direct inputs to valuation and estimate revisions.
Market effects
Signals continued strength in veterinary diagnostics recurring revenue and instrument placements, potentially supportive for sentiment across animal health diagnostics peers.
International CAG Diagnostics recurring revenue grew nearly 12% organically, suggesting non-US demand resilience.
Water and LPD growth plus reference lab volume gains indicate broad-based performance, reducing reliance on any single geography or modality.
Counterpoint
Wellness visit pressure is still described as the primary constraint to clinical visits, which could cap upside if it worsens despite instrument and consumables momentum.
Key entities
- companyIDEXX
Veterinary diagnostics and software company providing Q2 results and raising 2026 revenue and EPS outlook.
